Tag Archives: Orsini Specialty Pharmacy

hATTR-PN Drug WAINUA™ Available at Orsini Specialty Pharmacy

WAINUA™ for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis is available at Orsini Specialty Pharmacy

Takeda Selects Specialty Pharmacy Partners for ADZYNMA and FRUZAQLA

Takeda Pharmaceuticals Selects Specialty Pharmacy Partners for new FDA-approved drugs ADZYNMA and FRUZAQLA

Specialty Pharmacy News Roundup: October 2023

The following company announcements are just a few of the specialty pharmacy company activities from this month. Subscribe to AMI’s Specialty Pharmacy Database to stay up to date on company and industry trends

Specialty Pharmacy News Roundup: May 2023

The latest in specialty pharmacy news and research. Stay up to date on companies and industry trends at the forefront of the specialty pharmacy industry

Specialty Pharmacy News Roundup: April 2023

The latest in specialty pharmacy news and research. Stay up to date on companies and industry trends at the forefront of the specialty pharmacy industry. 

Specialty Pharmacy Limited Distribution Drug Agreements at Year-End 2022

The leading specialty pharmacies were busy signing limited distribution drug agreements at the end of 2022. Here’s a round-up of the activities

Orsini Specialty Pharmacy Continues Expansion Through Strategic Partnership

Investment positions Orsini Specialty Pharmacy for continued expansion of patient access and support services across therapies for highly complex and rare diseases

PantherRx Rare and Orsini Specialty Pharmacy Chosen as Partners for OXLUMO

Alnylam® Pharmaceuticals selected PantherRx Rare and Orsini Specialty Pharmacy as limited distribution partners for OXLUMO™ (lumasiran). OXLUMO is the first and only treatment approved for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. PH1 is an ultra-rare genetic disease characterized by the overproduction of oxalate, a waste product that […]